📰 Psychedelics News

Curated updates on microdosing, research, policy, and community.

Filters

2026-02-15 ScienceDaily Psychedelics

Psychedelics may work by shutting down reality and unlocking memory

Psychedelics can quiet the brain’s visual input system, pushing it to replace missing details with vivid fragments from memory. Scientists found that slow, rhythmic brain waves help shift perception away from the outs...

2026-02-13 The Microdose (Berkeley)

A bonanza of new state psychedelics bills, including ones to fund ibogaine research and new trigger laws for synthetic psilocybin

Plus: A death and other troubles at ibogaine centers in Mexico, and MAPS releases policy guidebook

2026-02-13 ICEERS

Psychedelic-Assisted Therapies in Spanish Congress

On February 13, 2026, the Ernest Lluch Chamber of the Congress of Deputies hosted Spain's first parliamentary conference dedicated to psychedelic-assisted psychotherapies, entitled “Innovation in mental health: psyche...

2026-02-13 The Psychedelic Blog (Substack)

When Psychedelics Expose Misalignment

Welcome to the Psychedelic Blog. I write about the impact of Psychedelics on Grieving, Relationships, Culture & Death.

2026-02-13 DoubleBlind Magazine

ChatGPT’s Drug Advice Under Scrutiny After Teen’s Overdose

Over the span of 18 months, a college student repeatedly turned to ChatGPT for drug safety advice. His case is now raising urgent questions. [...] Read More... The post ChatGPT’s Drug Advice Under Scrutiny After Teen’...

2026-02-13 Psychedelic Alpha

Q4’25 Psychedelic Lobbying Update

Each quarter, we provide a look at federal lobbying disclosures by psychedelic drug developers and nonprofits. Here, we share our analysis of the latest developments for our Pα+ subscribers.

2026-02-13 Chemical Collective

Psychedelics and Weight Loss

Oli Genn-Bash argues that while traditional weight loss focuses on calories, exercise, and willpower, psychedelics may indirectly support healthier habits and self-relationship by rewiring the brain, addressing trauma...

2026-02-11 Psychedelics Today

Ketamine Assisted Psychotherapy for Couples

Enamory is hosting a training for therapists interested in adding KAP to their couples therapy work. Learn more here. Some of the Enamory team were recently guests on the Psychedelics Today podcast. Listen here. The p...

2026-02-11 Psychedelics Today

Psychedelics, Depth, and the Human Psyche: Psychedelics, Depth, and the Human Psyche

Join us for a full-day virtual seminar on March 15th, where leading experts converge to explore the transformative intersection of psychedelic medicine, depth psychology, and collective healing. This immersive seminar...

2026-02-11 DoubleBlind Magazine

What Happens to Mushroom Science in a Post-Truth Internet?

It's all happening: Harmful mushroom advice, AI hallucinations, and the collapse of online trust. [...] Read More... The post What Happens to Mushroom Science in a Post-Truth Internet? appeared first on DoubleBlind Mag.

2026-02-11 Tripsitter (Substack)

What Ibogaine Can (and Can’t) Do: A Real Recovery Story

By the time Laura Shapiro found ibogaine, nothing else had worked — she was completely out of options.

2026-02-11 Chemical Collective

Psychedelics and Polysubstance Use: What to Avoid

Psychedelics are often mixed with other substances at parties, producing unpredictable and sometimes synergistic or risky effects. Because scientific research on such combinations is limited, harm-reduction knowledge ...

2026-02-11 Psychedelics Today

Dr. Chandra Khalifian and Dr. Kayla Knopp: Enamory, Ketamine and Couples Therapy

Enamory is a clinical practice, training institute, and nonprofit research organization focused on psychedelic assisted couples therapy. In this episode, clinical psychologists Chandra Khalifian and Kayla Knopp discus...

2026-02-10 PsyMed Ventures

The Future of Whole Brain Emulation

Whole brain emulation without the sci-fi, by PsyMed’s Danny Carbonero

2026-02-10 Psychedelic Alpha

Taking the Helm at Helus: A Brief Q&A With New CEO Michael Cola

Psychedelic Alpha’s Josh Hardman speaks with newly appointed Helus Pharma CEO Michael Cola in a brief Q&A on execution, regulatory rigor, and scaling serotonergic CNS medicines.